The goal of the Lymphoma Program's clinical research effort is to make the treatment of lymphoid malignancies more effective and specific, while also less toxic. Toward that goal, the program makes promising new therapies available to patients with a variety of lymphoid malignancies, in a carefully monitored setting, through clinical trials.
Current research focuses on targeting tumors with drugs directed against specific molecular targets in lymphoid malignancies, or with antibodies reactive against tumor cell surface proteins, alone or linked to radionucleotides. Another target of therapy is the tumor's "microenvironment" using inhibitors of angiogenesis (new blood vessel development) and stimulators of the immune response. Our team is also leading several clinical trials of CAR T-cell therapy for lymphoma.
Many members of the clinical research team also have active programs of laboratory-based investigation in lymphoid malignancies. Researchers work closely with other scientists within Harvard Medical School-affiliated institutions.
Featured Clinical Trials
Trial 22-467: An adaptive phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B-cell lymphoma
Principal Investigator: Caron A. Jacobson, MD, MMSc
Trial 24-253: A phase 1b open-label study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-hodgkin lymphoma
Principal Investigator: David Qualls, MD
Trial 22-632: A phase 2 study of glofitamab and obinutuzumab for first-line treatment of follicular lymphoma and marginal zone lymphoma
Principal Investigator: Reid W. Merryman, MD
Trial 22-702: A phase 2 study of epcoritamab and rituximab for first-line treatment of follicular lymphoma
Principal Investigator: Reid W. Merryman, MD
Trial 22-271: A phase 3 randomized, open-label, multicenter study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in subjects with relapsed/refractory follicular lymphoma
Principal Investigator: Caron A. Jacobson, MD, MMSc
Trial 21-040: A phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab in patients with Relapsed/refractory and previously untreated mantle cell lymphoma
Principal Investigator: Austin Kim, MD
Trial 24-104: Pilot study of glofitamab and lenalidomide in patients with relapsed or refractory mantle cell lymphoma previously treated with a BTK inhibitor
Principal Investigator: Christine Ryan, MD
Trial 24-017: A phase 2 study of fixed duration therapy with pirtobrutinib and obinutuzumab in previously untreated chronic lymphocytic leukemia (POP)
Principal Investigator: Inhye Ahn, MD
Trial 21-279: A phase 2 trial of zanubrutinib and venetoclax in previously treated CLL/SLL patients
Principal Investigator: Inhye Ahn, MD
Trial 23-429: A phase 2 study of glofitamab as monotherapy or in combination with polatuzumab vedotin or atezolizumab in Richter’s transformation
Principal Investigator: Matthew Davids, MD, MMSc
Trial 23-553: A randomized phase 3 interim response adapted trial comparing standard therapy with immunooncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma
Principal Investigator: Ann S. LaCasce, MD, MMSc
Trial 22-121: A phase 2 study of brentuximab vedotin plus nivolumab without stem cell consolidation in patients with relapsed/refractory classical Hodgkin lymphoma
Principal Investigator: Philippe Armand, MD, PhD
Trial 23-179: A phase II trial of pembrolizumab in combination with chimeric antigen receptor therapy in patients with relapsed/refractory primary mediastinal B-cell lymphoma
Principal Investigator: Jennifer Crombie, MD